LeBlanc, J. J., ElSherif, M., Mulpuru, S., Warhuus, M., Ambrose, A., Andrew, M., Boivin, G., Bowie, W., Chit, A., Dos Santos, G., Green, K., Halperin, S. A., Hatchette, T. F., Ibarguchi, B., Johnstone, J., Katz, K., Langley, J. M., Lagacé-Wiens, P., Loeb, M., ... McNeil, S. A. (2020). Validation of the Seegene RV15 multiplex PCR for the detection of influenza A subtypes and influenza B lineages during national influenza surveillance in hospitalized adults. Journal of Medical Microbiology, 69(2), 256-264. https://doi.org/10.1099/jmm.0.001032
LeBlanc, JJ, ElSherif, M, Mulpuru, S, Warhuus, M, Ambrose, A, Andrew, M, Boivin, G, Bowie, W, Chit, A, Dos Santos, G, Green, K, Halperin, SA, Hatchette, TF, Ibarguchi, B, Johnstone, J, Katz, K, Langley, JM, Lagacé-Wiens, P, Loeb, M, Lund, A, MacKinnon-Cameron, D, McCarthy, A, McElhaney, JE, McGeer, A, Poirier, A, Powis, J, Richardson, D, Semret, M, Shinde, V, Smyth, D, Trottier, S, Valiquette, L, Webster, D, Ye, L & McNeil, SA 2020, 'Validation of the Seegene RV15 multiplex PCR for the detection of influenza A subtypes and influenza B lineages during national influenza surveillance in hospitalized adults', Journal of Medical Microbiology, vol. 69, n.º 2, pp. 256-264. https://doi.org/10.1099/jmm.0.001032
@article{4b139bf0c7bb4cf8979fadf9f51abebb,
title = "Validation of the Seegene RV15 multiplex PCR for the detection of influenza A subtypes and influenza B lineages during national influenza surveillance in hospitalized adults",
abstract = "Background. The Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN SOS) has been performing active influenza surveillance since 2009 ( ClinicalTrials. gov identifier: NCT01517191). Influenza A and B viruses are identified and characterized using real-time reverse-transcriptase polymerase chain reaction (RT-PCR), and multiplex testing has been performed on a subset of patients to identify other respiratory virus aetiologies. Since both methods can identify influenza A and B, a direct comparison was performed. Methods. Validated real-time RT-PCRs from the World Health Organization (WHO) to identify influenza A and B viruses, characterize influenza A viruses into the H1N1 or H3N2 subtypes and describe influenza B viruses belonging to the Yamagata or Victoria lineages. In a subset of patients, the Seeplex RV15 One-Step ACE Detection assay (RV15) kit was also used for the detection of other respiratory viruses. Results. In total, 1111 nasopharyngeal swabs were tested by RV15 and real-time RT-PCRs for influenza A and B identification and characterization. For influenza A, RV15 showed 98.0 % sensitivity, 100 % specificity and 99.7 % accuracy. The performance characteristics of RV15 were similar for influenza A subtypes H1N1 and H3N2. For influenza B, RV15 had 99.2 % sensitivity, 100 % specificity and 99.8 % accuracy, with similar assay performance being shown for both the Yamagata and Victoria lineages. Conclusions. Overall, the detection of circulating subtypes of influenza A and lineages of influenza B by RV15 was similar to detection by real-time RT-PCR. Multiplex testing with RV15 allows for a more comprehensive respiratory virus surveillance in hospitalized adults, without significantly compromising the reliability of influenza A or B virus detection.",
author = "LeBlanc, {J. J.} and M. ElSherif and S. Mulpuru and M. Warhuus and A. Ambrose and M. Andrew and G. Boivin and W. Bowie and A. Chit and {Dos Santos}, G. and K. Green and Halperin, {S. A.} and Hatchette, {T. F.} and B. Ibarguchi and J. Johnstone and K. Katz and Langley, {J. M.} and P. Lagac{\'e}-Wiens and M. Loeb and A. Lund and D. MacKinnon-Cameron and A. McCarthy and McElhaney, {J. E.} and A. McGeer and A. Poirier and J. Powis and D. Richardson and M. Semret and V. Shinde and D. Smyth and S. Trottier and L. Valiquette and D. Webster and L. Ye and McNeil, {S. A.}",
note = "Funding Information: Influenza virus surveillance was funded by the Public Health Agency of Canada (PHAC) and the Canadian Institutes of Health Research (CIHR), and through a Collaborative Research Agreement between GlaxoSmith-Kline Biologicals SA and the CIRN SOS Network. CIRN and SM provided funding for RV15 testing. The authors received no financial support or other form of compensation related to the development of the manuscript, and were solely responsible for final manuscript content and data interpretation. Funding Information: J.L. received research grants from Merck for work outside the study, but no personal payments. T.F.H. and S.A.M. report payments to their institution from the GSK group of companies for the conduct of the study, and payments from Pfizer, Merck, Novartis and Sanofi‐Pasteur outside the submitted work. M.K.A. reports grants from the GSK group of companies, Pfizer and Sanofi, but no personal payments. J.M. reports payments to her institution from the GSK group of companies and Sanofi for her participation in advisory boards. A.P. reports payments from Actelion, Sanofi‐Pasteur and Genentech. J.P. reports payments from the GSK group of companies, Merck, Roche and Synthetic Biologics outside the submitted work. L.V. received research grants from the GSK group of companies, Pfizer, Optimer, Cubist and Merck, and personal fees from Merck, Optimer and Cubist. G.D.S. reports he was external consultant at Business and Decision Life Sciences (on behalf of GSK) at the time of the study, and is currently employed by the GSK group of companies and holds shares in the GSK group of companies. No other conflicts were declared. Publisher Copyright: {\textcopyright} 2020 The Authors.",
year = "2020",
doi = "10.1099/jmm.0.001032",
language = "English",
volume = "69",
pages = "256--264",
journal = "Journal of Medical Microbiology",
issn = "0022-2615",
publisher = "Society for General Microbiology",
number = "2",
}
TY - JOUR
T1 - Validation of the Seegene RV15 multiplex PCR for the detection of influenza A subtypes and influenza B lineages during national influenza surveillance in hospitalized adults
AU - LeBlanc, J. J.
AU - ElSherif, M.
AU - Mulpuru, S.
AU - Warhuus, M.
AU - Ambrose, A.
AU - Andrew, M.
AU - Boivin, G.
AU - Bowie, W.
AU - Chit, A.
AU - Dos Santos, G.
AU - Green, K.
AU - Halperin, S. A.
AU - Hatchette, T. F.
AU - Ibarguchi, B.
AU - Johnstone, J.
AU - Katz, K.
AU - Langley, J. M.
AU - Lagacé-Wiens, P.
AU - Loeb, M.
AU - Lund, A.
AU - MacKinnon-Cameron, D.
AU - McCarthy, A.
AU - McElhaney, J. E.
AU - McGeer, A.
AU - Poirier, A.
AU - Powis, J.
AU - Richardson, D.
AU - Semret, M.
AU - Shinde, V.
AU - Smyth, D.
AU - Trottier, S.
AU - Valiquette, L.
AU - Webster, D.
AU - Ye, L.
AU - McNeil, S. A.
N1 - Funding Information:
Influenza virus surveillance was funded by the Public Health Agency of Canada (PHAC) and the Canadian Institutes of Health Research (CIHR), and through a Collaborative Research Agreement between GlaxoSmith-Kline Biologicals SA and the CIRN SOS Network. CIRN and SM provided funding for RV15 testing. The authors received no financial support or other form of compensation related to the development of the manuscript, and were solely responsible for final manuscript content and data interpretation.
Funding Information:
J.L. received research grants from Merck for work outside the study, but no personal payments. T.F.H. and S.A.M. report payments to their institution from the GSK group of companies for the conduct of the study, and payments from Pfizer, Merck, Novartis and Sanofi‐Pasteur outside the submitted work. M.K.A. reports grants from the GSK group of companies, Pfizer and Sanofi, but no personal payments. J.M. reports payments to her institution from the GSK group of companies and Sanofi for her participation in advisory boards. A.P. reports payments from Actelion, Sanofi‐Pasteur and Genentech. J.P. reports payments from the GSK group of companies, Merck, Roche and Synthetic Biologics outside the submitted work. L.V. received research grants from the GSK group of companies, Pfizer, Optimer, Cubist and Merck, and personal fees from Merck, Optimer and Cubist. G.D.S. reports he was external consultant at Business and Decision Life Sciences (on behalf of GSK) at the time of the study, and is currently employed by the GSK group of companies and holds shares in the GSK group of companies. No other conflicts were declared.
Publisher Copyright:
© 2020 The Authors.
PY - 2020
Y1 - 2020
N2 - Background. The Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN SOS) has been performing active influenza surveillance since 2009 ( ClinicalTrials. gov identifier: NCT01517191). Influenza A and B viruses are identified and characterized using real-time reverse-transcriptase polymerase chain reaction (RT-PCR), and multiplex testing has been performed on a subset of patients to identify other respiratory virus aetiologies. Since both methods can identify influenza A and B, a direct comparison was performed. Methods. Validated real-time RT-PCRs from the World Health Organization (WHO) to identify influenza A and B viruses, characterize influenza A viruses into the H1N1 or H3N2 subtypes and describe influenza B viruses belonging to the Yamagata or Victoria lineages. In a subset of patients, the Seeplex RV15 One-Step ACE Detection assay (RV15) kit was also used for the detection of other respiratory viruses. Results. In total, 1111 nasopharyngeal swabs were tested by RV15 and real-time RT-PCRs for influenza A and B identification and characterization. For influenza A, RV15 showed 98.0 % sensitivity, 100 % specificity and 99.7 % accuracy. The performance characteristics of RV15 were similar for influenza A subtypes H1N1 and H3N2. For influenza B, RV15 had 99.2 % sensitivity, 100 % specificity and 99.8 % accuracy, with similar assay performance being shown for both the Yamagata and Victoria lineages. Conclusions. Overall, the detection of circulating subtypes of influenza A and lineages of influenza B by RV15 was similar to detection by real-time RT-PCR. Multiplex testing with RV15 allows for a more comprehensive respiratory virus surveillance in hospitalized adults, without significantly compromising the reliability of influenza A or B virus detection.
AB - Background. The Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN SOS) has been performing active influenza surveillance since 2009 ( ClinicalTrials. gov identifier: NCT01517191). Influenza A and B viruses are identified and characterized using real-time reverse-transcriptase polymerase chain reaction (RT-PCR), and multiplex testing has been performed on a subset of patients to identify other respiratory virus aetiologies. Since both methods can identify influenza A and B, a direct comparison was performed. Methods. Validated real-time RT-PCRs from the World Health Organization (WHO) to identify influenza A and B viruses, characterize influenza A viruses into the H1N1 or H3N2 subtypes and describe influenza B viruses belonging to the Yamagata or Victoria lineages. In a subset of patients, the Seeplex RV15 One-Step ACE Detection assay (RV15) kit was also used for the detection of other respiratory viruses. Results. In total, 1111 nasopharyngeal swabs were tested by RV15 and real-time RT-PCRs for influenza A and B identification and characterization. For influenza A, RV15 showed 98.0 % sensitivity, 100 % specificity and 99.7 % accuracy. The performance characteristics of RV15 were similar for influenza A subtypes H1N1 and H3N2. For influenza B, RV15 had 99.2 % sensitivity, 100 % specificity and 99.8 % accuracy, with similar assay performance being shown for both the Yamagata and Victoria lineages. Conclusions. Overall, the detection of circulating subtypes of influenza A and lineages of influenza B by RV15 was similar to detection by real-time RT-PCR. Multiplex testing with RV15 allows for a more comprehensive respiratory virus surveillance in hospitalized adults, without significantly compromising the reliability of influenza A or B virus detection.
UR - http://www.scopus.com/inward/record.url?scp=85080029560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080029560&partnerID=8YFLogxK
U2 - 10.1099/jmm.0.001032
DO - 10.1099/jmm.0.001032
M3 - Article
C2 - 31264957
AN - SCOPUS:85080029560
SN - 0022-2615
VL - 69
SP - 256
EP - 264
JO - Journal of Medical Microbiology
JF - Journal of Medical Microbiology
IS - 2
ER -